Abstract
The emergence of multidrug-resistant and extensively drug-resistant tuberculosis calls for novel approaches to treatment. Recent studies have shown that BlaC, the β-lactamase of Mycobacterium tuberculosis, is the major determinant of β-lactam resistance. This review invites the reader to explore evidence in order to answer the questions: can β-lactam and β-lactamase inhibitors adequately treat M. tuberculosis infection and are they a viable option in the management of resistant tuberculosis today?
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Antitubercular Agents / pharmacology
-
Antitubercular Agents / therapeutic use*
-
Bacterial Proteins / antagonists & inhibitors*
-
Bacterial Proteins / chemistry
-
Cell Wall / drug effects
-
Humans
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / genetics
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
beta-Lactamase Inhibitors*
-
beta-Lactamases / chemistry
-
beta-Lactams / pharmacology
-
beta-Lactams / therapeutic use*
Substances
-
Antitubercular Agents
-
Bacterial Proteins
-
beta-Lactamase Inhibitors
-
beta-Lactams
-
beta-Lactamases